Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Leveragen Announces Collaboration with Moderna to Advance Antibody Technology
Details : Under the agreement, Leveragen will employ its proprietary antibody discovery platform to generate a panel of optimized binding modules against therapeutic targets selected by Moderna.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 30, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?